The rise of Viagra and its influence on the medicinal landscape presents a complex question for traders. While the first sales figures were remarkable, the intellectual property has lapsed, leading to a deluge of generic alternatives that are chipping away at earnings. In addition, the sector is facing challenges related to aging trends and evolvin